Cardlytics (NASDAQ:CDLX) Price Target Cut to $12.00

Cardlytics (NASDAQ:CDLX) had its target price decreased by Craig Hallum from $18.00 to $12.00 in a research report issued on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Craig Hallum’s target price indicates a potential upside of 32.74% from the stock’s previous close.

A number of other analysts also recently commented on the stock. Lake Street Capital boosted their price target on shares of Cardlytics from $13.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, March 15th. Needham & Company LLC decreased their price target on Cardlytics from $17.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday.

Cardlytics Stock Performance

NASDAQ:CDLX traded down $5.56 during midday trading on Thursday, reaching $9.04. 6,888,130 shares of the company traded hands, compared to its average volume of 1,525,006. Cardlytics has a twelve month low of $4.94 and a twelve month high of $20.52. The company has a debt-to-equity ratio of 1.91, a current ratio of 1.31 and a quick ratio of 1.31. The company has a fifty day moving average price of $12.51 and a 200 day moving average price of $9.74. The firm has a market capitalization of $435.49 million, a price-to-earnings ratio of -2.52 and a beta of 1.50.

Cardlytics (NASDAQ:CDLX) last released its quarterly earnings data on Thursday, March 14th. The company reported ($0.14) earnings per share for the quarter. The firm had revenue of $89.17 million during the quarter. Cardlytics had a negative return on equity of 25.38% and a negative net margin of 43.56%.

Insider Activity

In related news, insider Nicholas Hollmeyer Lynton sold 12,460 shares of Cardlytics stock in a transaction dated Tuesday, April 2nd. The stock was sold at an average price of $13.69, for a total value of $170,577.40. Following the transaction, the insider now owns 71,355 shares of the company’s stock, valued at approximately $976,849.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Cardlytics news, insider Nicholas Hollmeyer Lynton sold 12,460 shares of Cardlytics stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $13.69, for a total transaction of $170,577.40. Following the transaction, the insider now directly owns 71,355 shares in the company, valued at approximately $976,849.95. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Amit Gupta sold 23,416 shares of the firm’s stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $11.91, for a total value of $278,884.56. Following the completion of the sale, the chief operating officer now directly owns 122,676 shares of the company’s stock, valued at approximately $1,461,071.16. The disclosure for this sale can be found here. In the last 90 days, insiders sold 36,306 shares of company stock worth $455,203. Insiders own 4.40% of the company’s stock.

Institutional Investors Weigh In On Cardlytics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Deutsche Bank AG increased its position in Cardlytics by 5.0% in the 3rd quarter. Deutsche Bank AG now owns 43,992 shares of the company’s stock worth $726,000 after purchasing an additional 2,093 shares during the last quarter. Check Capital Management Inc. CA increased its stake in shares of Cardlytics by 14.0% during the 4th quarter. Check Capital Management Inc. CA now owns 23,200 shares of the company’s stock worth $214,000 after purchasing an additional 2,850 shares during the last quarter. Brown Advisory Inc. raised its holdings in shares of Cardlytics by 1.7% during the 4th quarter. Brown Advisory Inc. now owns 199,633 shares of the company’s stock valued at $1,839,000 after purchasing an additional 3,257 shares in the last quarter. Susquehanna Fundamental Investments LLC lifted its stake in shares of Cardlytics by 13.8% in the 1st quarter. Susquehanna Fundamental Investments LLC now owns 31,536 shares of the company’s stock valued at $457,000 after purchasing an additional 3,836 shares during the last quarter. Finally, SG Americas Securities LLC boosted its holdings in Cardlytics by 34.3% in the fourth quarter. SG Americas Securities LLC now owns 21,461 shares of the company’s stock worth $198,000 after purchasing an additional 5,484 shares in the last quarter. Hedge funds and other institutional investors own 68.10% of the company’s stock.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.